Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Lexaria Bioscience's change in inventory for the quarter that ended in May. 2026 was $0.00 Mil. It means Lexaria Bioscience's inventory
stayed the same
from Feb. 2026 to May. 2026 .
Lexaria Bioscience's change in inventory for the fiscal year that ended in Aug. 2025 was $0.00 Mil. It means Lexaria Bioscience's inventory
stayed the same
from Aug. 2024 to Aug. 2025 .
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Lexaria Bioscience's Inventory to Revenue for the quarter that ended in May. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lexaria Bioscience Change In Inventory Related Terms
Lexaria Bioscience Change In Inventory Historical Data
* Premium members only.
The historical data trend for Lexaria Bioscience's Change In Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lexaria Bioscience Change In Inventory Calculation
Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.
Change In Inventory for the trailing twelve months (TTM) ended in May. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Change In Inventory of $0.00 Mil mean?
Lexaria Bioscience (LEXX) has a Change In Inventory of $0.00 Mil as of May. 2026. Change in Inventory is the difference between current-period inventory and past-period inventory. View historical data for Lexaria Bioscience and its competitors.
Is Lexaria Bioscience's Change In Inventory too high?
Lexaria Bioscience's current Change In Inventory is $0.00 Mil. Overall, Lexaria Bioscience has a GF Score™ of 22/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Lexaria Bioscience's Change In Inventory compare to CTXR and PTN?
Lexaria Bioscience's Change In Inventory of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Inventory for a Biotechnology company?
A good Change In Inventory depends on the Biotechnology industry context. However, Change In Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Inventory mean?
A high Change In Inventory can signal that a stock is expensive relative to its fundamentals. Change in Inventory is the difference between current-period inventory and past-period inventory. View historical data for Lexaria Bioscience and its competitors. Lexaria Bioscience's current Change In Inventory is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lexaria Bioscience stock overvalued right now?
Based on GuruFocus' analysis, Lexaria Bioscience (LEXX) is currently considered Fairly Valued. The stock's GF Value™ is $0.37, compared to a current price of $0.40 — trading 7.1% above its estimated fair value. The current Change In Inventory is $0.00 Mil. Lexaria Bioscience's overall GF Score™ is 22/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Inventory calculated?
Change In Inventory is calculated from a company's financial statements. For Lexaria Bioscience (LEXX), the current Change In Inventory is $0.00 Mil as of May. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lexaria Bioscience (LEXX) Overvalued in 2026?
Based on GuruFocus' analysis, Lexaria Bioscience stock appears to be overvalued.
The current stock price of $0.40 is trading 7.1% above its estimated GF Value™ of $0.37.
GuruFocus considers Lexaria Bioscience to be Fairly Valued.
Key valuation signals for LEXX:
Change In Inventory: $0.00 Mil
GF Value™: $0.37 vs. price of $0.40 (7.1% above fair value)
No single metric tells the full story. See the LEXX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lexaria Bioscience Corp is a biotechnology company focused on enhancing the bioavailability of active pharmaceutical ingredients using its patented DehydraTECH drug delivery technology. DehydraTECH improves absorption, effectiveness, and tolerability and can be applied to APIs such as GLP-1 and GIP drugs, vitamins, pain medications, hormones, antivirals, nicotine and cannabinoids across therapeutic areas including diabetes, weight loss, epilepsy, hypertension, and heart disease. It can be used in formats such as tablets, capsules, oral suspensions, foods, beverages, and pouches, and supports pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The Company operates one segment: IP licensing, generating revenue from licensing its DehydraTECH technology.
22GF Score
Get the complete analysis for LEXX
Change In Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LEXX has been successfully added to your 
